Parameter
| Biomarker | NfL | Full name | Neurofilament Light Chain | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prognosis, Disease Monitoring |
| Disease | Amyotrophic Lateral Sclerosis | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Plasma/CSF (SIMOA, ELISA, Luminex) | ||
| Pathobiological Mechanisms | Released after neuronal axonal injury, directly reflecting the degree of pan-neurodegeneration, synchronized with motor function decline. | ||||
| Clinical Availability Status | Clinically available (under FDA qualification) | ||||
| Notes and Dynamics | Plasma NfL >20pg/mL indicates rapid progression; combined with pNfH can distinguish ALS from benign muscular atrophy; used as a neuroprotective efficacy endpoint in phase II clinical trials. | ||||